ArticleBlood cancer journal2015

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.

C C Bjorklund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.